Bal Pharma Ltd

Bal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bal Pharma Ltd

₹ 100 2.03%
26 Apr - close price
balpharma.com BSE: 524824 NSE : BALPHARMA
About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Key Points

Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.

Website BSE NSE
  • Market Cap ₹ 159 Cr.
  • Current Price ₹ 100
  • High / Low ₹ 132 / 71.0
  • Stock P/E 25.6
  • Book Value ₹ 61.6
  • Dividend Yield 1.00 %
  • ROCE 10.2 %
  • ROE 6.65 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 19.7%

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of 9.27% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
62.70 70.29 70.61 67.00 68.99 73.76 69.51 75.05 76.56 81.97 70.17 92.30 81.49
56.47 63.33 63.40 60.59 62.88 70.27 64.06 69.04 70.25 73.70 63.33 84.64 73.87
Operating Profit 6.23 6.96 7.21 6.41 6.11 3.49 5.45 6.01 6.31 8.27 6.84 7.66 7.62
OPM % 9.94% 9.90% 10.21% 9.57% 8.86% 4.73% 7.84% 8.01% 8.24% 10.09% 9.75% 8.30% 9.35%
0.64 1.17 0.53 0.91 1.11 3.94 0.56 0.38 0.77 0.44 0.45 0.41 0.26
Interest 2.89 3.12 3.02 2.58 2.36 2.45 2.37 2.83 3.12 3.84 3.64 3.82 3.66
Depreciation 1.64 2.33 1.70 1.72 1.71 2.11 1.83 1.96 2.03 1.66 2.12 2.02 2.55
Profit before tax 2.34 2.68 3.02 3.02 3.15 2.87 1.81 1.60 1.93 3.21 1.53 2.23 1.67
Tax % 34.19% -63.43% 49.34% -0.99% 61.27% 3.14% 22.10% 29.38% 23.83% 33.64% 22.22% 28.25% 25.15%
1.55 4.38 1.53 3.05 1.22 2.78 1.41 1.13 1.47 2.12 1.20 1.60 1.26
EPS in Rs 1.09 2.95 1.03 2.06 0.82 1.88 0.91 0.73 0.94 1.35 0.76 1.02 0.80
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
140 148 179 187 198 226 210 223 171 249 280 303 326
125 131 161 170 181 206 187 203 164 223 257 277 296
Operating Profit 15 17 18 18 17 20 23 20 7 27 23 26 30
OPM % 11% 12% 10% 9% 9% 9% 11% 9% 4% 11% 8% 9% 9%
1 1 1 1 2 3 2 3 4 3 6 2 2
Interest 7 8 7 7 6 8 9 13 13 12 11 12 15
Depreciation 4 5 5 7 7 6 7 6 7 7 7 7 8
Profit before tax 4 5 7 5 5 9 8 4 -9 10 12 9 9
Tax % 14% 16% 23% 23% 46% 38% 30% -53% 2% 7% 29% 28%
4 4 5 4 3 5 6 7 -9 9 9 6 6
EPS in Rs 3.56 4.05 4.56 3.12 2.18 3.75 4.19 4.77 -6.28 6.14 5.79 3.91 3.93
Dividend Payout % 0% 19% 22% 32% 46% 27% 24% 21% 0% 16% 17% 26%
Compounded Sales Growth
10 Years: 7%
5 Years: 8%
3 Years: 21%
TTM: 11%
Compounded Profit Growth
10 Years: 4%
5 Years: 1%
3 Years: 39%
TTM: -9%
Stock Price CAGR
10 Years: 11%
5 Years: 7%
3 Years: -2%
1 Year: 22%
Return on Equity
10 Years: 7%
5 Years: 5%
3 Years: 9%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 11 11 11 13 13 14 14 14 14 15 15 16 16
Reserves 29 33 37 41 42 52 58 63 52 64 72 80 82
57 53 51 49 70 74 91 104 99 104 98 125 135
44 53 56 61 69 78 88 76 74 78 104 126 139
Total Liabilities 141 150 155 164 193 219 251 257 239 262 290 348 372
53 52 55 52 56 60 58 57 56 53 53 63 63
CWIP 0 1 0 1 4 2 0 0 0 0 1 0 0
Investments 0 0 0 1 1 0 7 7 7 8 8 8 8
88 97 99 110 132 157 185 193 176 200 227 276 300
Total Assets 141 150 155 164 193 219 251 257 239 262 290 348 372

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
13 16 13 14 1 6 13 12 22 10 31 5
-2 -4 -7 -6 -14 -8 -16 -12 -3 -7 -13 -22
-10 -11 -8 -7 12 2 4 0 -20 -3 -17 17
Net Cash Flow 1 2 -2 2 -0 0 1 -0 -2 0 -0 0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 100 107 93 88 105 99 111 107 110 102 101 114
Inventory Days 160 157 122 132 145 171 240 217 291 146 162 210
Days Payable 128 150 129 142 163 168 183 148 170 118 158 195
Cash Conversion Cycle 132 115 86 78 87 101 168 176 232 130 105 129
Working Capital Days 104 99 98 94 110 122 162 179 206 180 154 175
ROCE % 11% 13% 14% 12% 10% 13% 12% 10% 2% 13% 12% 10%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
44.84% 46.87% 49.57% 49.57% 52.00% 52.00% 51.61% 51.61% 51.61% 51.61% 51.24% 51.24%
0.00% 0.15% 0.31% 0.31% 0.30% 0.20% 0.18% 0.17% 0.17% 0.14% 0.13% 0.13%
55.16% 52.98% 50.12% 50.12% 47.71% 47.80% 48.21% 48.23% 48.23% 48.25% 48.64% 48.64%
No. of Shareholders 16,53116,31916,04916,22316,31716,17016,46616,02915,86915,52915,06014,772

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

  • Feb 2023
    Transcript
    Notes
    PPT
  • Sep 2022
    Transcript
    Notes
    PPT
  • Sep 2022
    Transcript
    Notes
    PPT